{"id":3626997,"date":"2023-10-12T14:31:28","date_gmt":"2023-10-12T18:31:28","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/?post_type=story&p=3626997"},"modified":"2023-10-12T14:31:29","modified_gmt":"2023-10-12T18:31:29","slug":"mercks-legacy-of-antimicrobial-innovation-and-action","status":"publish","type":"story","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/stories\/mercks-legacy-of-antimicrobial-innovation-and-action\/","title":{"rendered":"Merck’s legacy of antimicrobial innovation and action"},"content":{"rendered":"\n
\n
\n \n \n Innovation<\/small>\n <\/a>\n \n \n

\n Merck’s legacy of antimicrobial innovation and action\n <\/h1>\n

Delivering on our commitment to fight infectious diseases for more than a century<\/p>\n <\/div>\n\n

\n

October 12, 2023<\/p>\n

\n

Share this article<\/p>\n

\n \nFacebook icon<\/title><\/svg>\n<\/a><\/p>\n

\n\n\n\n\t.st0{fill:#00857C;}\n\n\nX icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nLinkedin icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nEmail icon<\/title><\/svg>\n<\/a><\/p>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n \n \n \n \"scientist\n <\/picture>\n\n <\/figure>\n \n <\/div>\n <\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n

For more than 100 years, Merck has contributed to the\u202fdiscovery\u202fand development of novel medicines and\u202fvaccines to fight infectious\u202fdiseases. With the growing burden of antimicrobial resistance (AMR), we’ve focused on stopping the increasing threat of AMR<\/a>. <\/p>\n\n\n

\n
\n\t\t\t\t\t\t\t
\n\t\t\t\t \n \n \n \n \n \n \n <\/picture>\n\t\t\t\t <\/div>\n\t\t
\n\t\t\t\n\t\t\t

\n <\/h3 >\n\t\t\t\n\t\t\t

1930s<\/h1>\n

Merck Research Laboratories played a central role in the development of sulfas, the first synthetic antimicrobial.<\/p>\n<\/div>\n\t\t\t\n

\n\t\t\t\t\t\t\t\t\t\t\t\t <\/div>\n <\/div>\n <\/div>\n<\/div>\n
\n
\n
\n